Traders should monitor for any post-webinar commentary or analyst takeaways that may influence sentiment around EB613's commercial potential, but no material data is expected. The next significant catalyst will be Phase 3 trial initiation or FDA feedback on the protocol.
Price Chart
Executive Summary
Entera Bio announced a virtual Key Opinion Leader webinar on April 20, 2026, to discuss the osteoporosis treatment landscape and its lead candidate, EB613, an oral PTH tablet. The event will feature prominent experts in bone health and aims to position EB613 as a potential first-in-class oral anabolic therapy for postmenopausal osteoporosis. This is a promotional and educational event, not a clinical or financial update.
Key Facts
- Entera Bio will host a KOL webinar on April 20, 2026, at 11:00 AM ET to discuss EB613 and the osteoporosis treatment landscape.
- Speakers include Dr. Felicia Cosman (Columbia University) and Dr. Steven Goldstein (NYU), both recognized experts in osteoporosis and women's health.
- EB613 is an oral, once-daily anabolic tablet for osteoporosis that completed a Phase 2 trial with positive biomarker and BMD results.
- In March 2026, Entera submitted a full Phase 3 protocol and statistical plan to the FDA under an IND 505(b)(2) pathway.
- No new clinical data, financial results, or regulatory decisions were announced.
Financial Impact
No immediate financial impact — no revenue, earnings, or funding details disclosed.
Risk Factors
- Webinar may generate speculative interest without substantive data, leading to short-term volatility.
- Delays in Phase 3 initiation or FDA feedback could negatively impact valuation given the company's small market cap and development-stage status.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273411 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | DEF 14A | $2.77 | awaiting T+60 | — | $2.86 (+3.25%) |
Oct 6, 2026 20d ago | 8-K | $2.53 | awaiting T+60 | — | $2.86 (+13.04%) |
Aug 27, 2026 8w ago | Press Release | $3.08 | awaiting T+60 | — | $2.86 (−7.14%) |
Aug 18, 2026 9w ago | 8-K | $2.89 | awaiting T+60 | — | $2.86 (−1.04%) |
Aug 7, 2026 11w ago | Press Release | $3.04 | awaiting T+60 | — | $2.86 (−5.92%) |
Jul 29, 2026 12w ago | Press Release | $3.00 $3.02 | ▲ +0.67% | ▼ −4.06% | $2.86 (−4.67%) |
Jun 16, 2026 18w ago | Press Release | $1.18 $2.79 | ▲ +136.44% | ▲ +135.44% | $2.86 (+142.37%) |
May 28, 2026 21w ago | Press Release | $1.22 $3.23 | ▲ +164.75% | ▲ +163.02% | $2.86 (+134.43%) |
May 18, 2026 23w ago | EFFECT | $1.23 $2.80 | ▲ +127.64% | ▲ +122.79% | $2.86 (+132.52%) |
May 8, 2026 24w ago | S-3 | $1.17 $2.81 | ▲ +140.17% | ▲ +135.78% | $2.86 (+144.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers